Understanding lung cancer risk through DNA repair tests and blood samples
Analysis of the predictability of lung cancer using DNA Repair functional assays and cryopreserved blood samples of the PLCO prospective cohort
This study is looking at how well our bodies can fix DNA damage to see if it can help predict who might be at risk for lung cancer, using blood samples from people in a large health study, so we can improve ways to prevent and catch lung cancer early for those who need it.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weizmann Institute of Science NIH-funded |
| Lab location | 1 site (Rehovot, Israel) |
| Project ID | NIH-11098755 on NIH RePORTER |
What this research studies
This research investigates how DNA repair capabilities can predict the risk of lung cancer by analyzing blood samples from participants in the PLCO cohort. It focuses on measuring the effectiveness of specific enzymes involved in repairing DNA damage, which may indicate an individual's susceptibility to developing lung cancer. By comparing DNA repair scores between healthy individuals and those with lung cancer, the study aims to enhance current risk prediction models. This could lead to better prevention strategies and earlier detection of lung cancer for at-risk individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of lung cancer, those with a history of smoking, and individuals exposed to environmental or occupational carcinogens.
Not a fit: Patients who have already been diagnosed with advanced lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for predicting lung cancer risk, allowing for earlier interventions and better patient outcomes.
How similar studies have performed: Previous studies have shown promising results in using DNA repair scores to predict lung cancer risk, indicating that this approach may be effective.
Where this research is happening
Rehovot, Israel
- Weizmann Institute of Science — Rehovot, Israel (Active)
Researchers
- Principal investigator: Livneh, Zvi — Weizmann Institute of Science
- Study coordinator: Livneh, Zvi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.